Sight Sciences, Inc. SGHT Surgical Glaucoma — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sight Sciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sight Sciences, Inc.'s surgical glaucoma — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sight Sciences, Inc.'s surgical glaucoma — gross profit?
- Sight Sciences, Inc. (SGHT) reported surgical glaucoma — gross profit of $16M in Q1 2026.
- How has Sight Sciences, Inc.'s surgical glaucoma — gross profit changed year-over-year?
- Sight Sciences, Inc.'s surgical glaucoma — gross profit increased by 8.0% year-over-year, from $14.82M to $16M.
- What is the long-term trend for Sight Sciences, Inc.'s surgical glaucoma — gross profit?
- Over 4 years (2021 to 2025), Sight Sciences, Inc.'s surgical glaucoma — gross profit has grown at a 13.2% compound annual growth rate (CAGR), from $40.02M to $65.69M.
- What does surgical glaucoma — gross profit mean?
- This metric represents the residual profit earned from the surgical glaucoma segment after deducting the direct costs of goods and services sold from the total segment revenue. It measures the fundamental profitability of the segment's product portfolio before accounting for operating expenses like research and development or marketing. A stable or expanding gross profit margin indicates strong pricing power and efficient production management.